China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that innovative drug CMS-D003 capsules (“CMS-D003”) self-developed by the Group has been granted approval for drug clinical trials by National Medical Products Administration of the People’s Republic of China (“NMPA”) on 11 March 2025. The approval was obtained on 12 March 2025. The NMPA grants the Group consent to conduct a clinical trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of CMS-D003 in both healthy adults and adult patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in China. CMS-D003 CMS-D003 is a small molecule cardiac myosin inhibitor, which is a targeted therapy for hypertrophic cardiomyopathy. By targeting inhibition of cardiac myosin adenosine triphosphate (ATP) enzymes, it inhibits myosin-actin interactions, reduces myofilament sliding, inhibits myocardial over-contraction, and improves diastolic dysfunction of the heart, thereby alleviating the patient’s clinical symptoms[1]. CMS-D003 demonstrates a short half-life, minimal risk for drug […]
Learn More
In February 11th 2025, with a Corporate Sustainability Assessment (CSA) score of 61, surpassing 93% of global peers, China Medical System Holdings Limited (“CMS” or the “Group”) has been included in the S&P Global Sustainability Yearbook 2025 (the “Yearbook 2025”). This marks the Group’s first inclusion in the global edition of S&P Global Sustainability Yearbook (the “Yearbook”), following the S&P Global Sustainability Yearbook (China Edition) inclusion for consecutive two years. Source: S&P Global Since its launch in 2008, the Yearbook’s professionalism and authority have been highly recognized by global ESG investors and other stakeholders. The Yearbook aims to identify outstanding companies in sustainable development from each industry. 7,690 companies across 62 industries were assessed, while only 780 stood out and were included in the Yearbook 2025. The inclusion in the Yearbook 2025 represents a high recognition of sustainable development practices of CMS. CMS has been actively responding […]
Learn MoreThe news on this page is intended to share cutting-edge medical information and is for academic reference only by medical and health professionals, not for advertising purposes. CMS does not recommend any drugs, medical devices and/or indications. The news information on this page is for reference only. Please follow the advice or guidance of your doctor or other healthcare professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. If you have understood and confirmed the above content, please click OK to enter.
